LYRA

Lyra Therapeutics, Inc.

0.34 USD
+0.01 (+1.66%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Lyra Therapeutics, Inc. stock is down -93.48% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 4 May’s closed higher than April. In the last 9 Unusual Options Trades, there were 6 PUTs, 3 CALLs. 25% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
15 Apr 19:49 19 Jul, 2024 5.00 PUT 413 72
15 Apr 19:49 19 Jul, 2024 5.00 PUT 566 72
15 Apr 19:49 19 Jul, 2024 5.00 PUT 244 72
15 Apr 19:49 19 Jul, 2024 7.50 CALL 566 229
15 Apr 19:49 19 Jul, 2024 7.50 CALL 575 229
15 Apr 19:49 19 Jul, 2024 7.50 CALL 377 229
15 Apr 19:49 19 Jul, 2024 5.00 PUT 343 72
15 Apr 19:49 19 Jul, 2024 5.00 PUT 576 72
07 May 15:55 17 May, 2024 2.50 PUT 152 49

About Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc. focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial.

  • HC Wainwright & Co.
    Tue May 7, 09:46
    hold
    downgrade
  • Jefferies
    Tue May 7, 08:03
    hold
    downgrade
  • BTIG
    Mon May 6, 11:57
    hold
    downgrade
  • HC Wainwright & Co.
    Wed May 1, 06:29
    buy
    confirm